RGT 419B
Alternative Names: RGT-419BLatest Information Update: 07 Oct 2024
At a glance
- Originator Regor Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Cyclin-dependent kinase 2 inhibitors; Cyclin-dependent kinase 4 inhibitors; Cyclin-dependent kinase 6 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I HER2 negative breast cancer; Solid tumours
Most Recent Events
- 30 Sep 2024 Genentech acquires RGT 419B from Regor
- 05 Feb 2024 Efficacy and adverse events data from a phase Ia trial in HER2-negative breast cancer presented at the 46th Annual San Antonio Breast Cancer Symposium (SABCS-2023)
- 07 Dec 2023 Efficacy, adverse events and pharmacokinetics data from a phase Ia trial in HER2-negative breast cancer released by Regor Therapeutics